The Secretary for Health of Hong Kong SAR, Professor Lo Chung-mau, met multinational pharmaceutical and healthcare companies in Zurich, Switzerland to present policy measures aimed at strengthening Hong Kong’s drug evaluation, clinical trials, and biomedical innovation capabilities.

• Measures presented include “primary evaluation” for new drugs, the Greater Bay Area International Clinical Trial Institute, and the planned Hong Kong Centre for Medical Products Regulation.
• The roundtable took place on 20 May 2026 in Zurich; the delegation is scheduled to return to Hong Kong on 22 May 2026.
• Companies were encouraged to use Hong Kong’s “1+” drug approval mechanism and participate in clinical trials in Hong Kong, including utilisation of Hong Kong-registered drugs and medical devices in Greater Bay Area Mainland cities.

This summary is based on a press release issued by the Government of the Hong Kong Special Administrative Region.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.